Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122000315?via=ihub
Empagliflozin proves benefit on health status in the non-diabetic, ethnic minority represented, EMPATROPISM trial population. * A significant mean improvement of 22 points in Kansas City Cardiomyopathy Questionnaire (KCCQ) was...
/>
Conclusions: Empagliflozin benefits quality of life in the non-diabetic, ethnic minority represented, EMPATROPISM trial population.
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35092583/
Introduction: AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure (HF). The safety and pharmacokinetics (PK) of AMG 986 in...
Conclusions: The results of this study support the enrollment of HF patients with RI to clinical trials of AMG 986 without the need for dose adjustments.
Mesenchymal Stromal Cell Exosomes in Cardiac Repair - Current Cardiology Reports
Source : https://link.springer.com/article/10.1007/s11886-022-01660-1
Purpose of the Review Mesenchymal stromal cells (MSCs) are considered an attractive option for cell-based therapy because of their immune-privileged phenotype and paracrine activity. Substantial preclinical evidence indicates that MSC...
Conclusion/Relevance: MSC Exosomes appear to be leading candidates to treat myocardial infarction and subsequent heart failure by carrying rich cargo from their parental cells. However, more clinical and pre-clinical studies on MSC exosomes will be required to confirm the beneficial effect to treat cardiovascular diseasesinterventions for...
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-022-00985-0
Purpose of Review This review highlights major studies across a broad array of topics presented at the virtual 2021 American Heart Association (AHA) Scientific Sessions. Recent Findings.
Conclusion: Research presented at the 2021 AHA Scientific Sessions emphasized the importance of interventions for cardiovascular disease prevention.
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors - Diabetes Therapy
Source : https://link.springer.com/article/10.1007/s13300-022-01204-4
Heart failure with preserved ejection fraction (HFpEF) is a condition with increasing disease burden. Prevalence of HFpEF is increasing, reflecting an increasingly elderly and comorbid population, as well as reinforcing...
Conclusion/Relevance: The European Society of Cardiology (ESC) recently added SGLT2 inhibitors to their guidelines for treatment of heart failure with reduced ejection fraction (HFrEF) following DAPA-HF and EMPEROR-Reduced trials and we suggest that similar changes be made to guidelines to support the use of SGLT2 inhibitors in the management...